INBS

Revenue: As of FY2027 Q1, the actual value is USD 1.392 M.

EPS: As of FY2027 Q1, the actual value is USD -0.86.

EBIT: As of FY2027 Q1, the actual value is USD -2.667 M.

Revenue

Total revenue for Intelligent Bio Solutions Inc. was $1.39 million for the fiscal first quarter ended September 30, 2026, marking a 25% year-over-year increase and a 21% sequential increase . This quarter’s revenue surpassed the Company’s prior quarterly record of $1,145,802 set in the fourth quarter of fiscal 2026 . Cartridge sales reached $845,583, representing 61% of total Q1 revenue, and grew 32% year-over-year and 35% sequentially . Other sales amounted to $281,253, an increase of 52% year-over-year, accounting for 20% of Q1 revenue . Cartridge sales contributed 73% to the $280,038 year-over-year increase in total revenue, rising to 61% of quarterly revenue from 58% a year ago .

Gross Profit

Gross profit was $758,004, up 46% year-over-year . The gross profit margin expanded to 54.5%, an increase from 46.6% in the prior-year quarter, reflecting an improvement of approximately 790 basis points year-over-year .

Operating Expenses (Three Months Ended September 30, 2026 vs. 2025)

• Selling, general and administrative expenses were - $2,579,641 in 2026 compared to - $2,706,889 in 2025 .
• Development and regulatory approval expenses were - $829,544 in 2026 compared to - $486,169 in 2025 .
• Depreciation and amortization were - $237,067 in 2026 compared to - $257,907 in 2025 .
• Impairment of long-lived assets was - $0 in 2026 compared to - $261,780 in 2025 .
• Total operating expenses were - $3,646,252 in 2026 compared to - $3,712,745 in 2025 .

Loss from Operations

Loss from operations was - $2,682,747 for the three months ended September 30, 2026, compared to - $3,001,187 for the same period in 2025 .

Net Loss

Net loss was - $2,668,435 for the three months ended September 30, 2026, compared to - $2,994,992 for the same period in 2025 . The net loss attributable to Intelligent Bio Solutions Inc. was - $2,658,302 in 2026, an improvement from - $2,983,006 in 2025 .

Cash and Cash Equivalents

Cash and cash equivalents totaled $5.93 million at September 30, 2026, up from $3.99 million at June 30, 2026 .

Operational Metrics

As of September 30, 2026, Intelligent Bio Solutions Inc. had 516 active customer accounts, with 27 new accounts added during the quarter . The Company’s reader installed base reached 1,978 units . Intelligent Bio Solutions Inc. submitted its 510(k) premarket notification to the FDA on September 9, 2026, for its Intelligent Fingerprinting Drug Screening System, seeking clearance for the detection of opiate codeine . The submission included a method comparison study demonstrating accuracy above 98%, sensitivity above 94%, and specificity of 100% . The Company also completed its 510(k) clinical program during the quarter and achieved ISO 13485:2016 recertification for its Intelligent Fingerprinting Drug Screening business .

Outlook

Management expects continued growth through fiscal 2027, driven by planned entry into the U.S. drug screening market . Intelligent Bio Solutions Inc. intends to invest in clinical and regulatory work for its 510(k) submission . The Company plans to maintain discipline across other business areas .